Phaseline

Companies › Endeavor Biomedicines

Endeavor Biomedicines: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Taladegib (ENV-101)
Smoothened homolog antagonist
SMOPhase 2Idiopathic Pulmonary Fibrosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06422884Taladegib (ENV-101)Phase 2Idiopathic Pulmonary FibrosisRespiratoryOct 2026
NCT07454291Taladegib (ENV-101)Phase 1Idiopathic Pulmonary FibrosisRespiratoryOct 2026

Targets

SMO (1)

Companies with the same targets

–

Companies built like this

Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.